Pliant Therapeutics, Inc.
PLRX
$1.56
$0.074.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -22.87% | -13.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.78% | -22.64% | |||
| Operating Income | 37.78% | 22.64% | |||
| Income Before Tax | 39.26% | 22.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.26% | 22.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.26% | 22.91% | |||
| EBIT | 37.78% | 22.64% | |||
| EBITDA | 38.13% | 22.81% | |||
| EPS Basic | 39.28% | 23.11% | |||
| Normalized Basic EPS | 39.06% | 23.11% | |||
| EPS Diluted | 39.28% | 23.11% | |||
| Normalized Diluted EPS | 39.06% | 23.11% | |||
| Average Basic Shares Outstanding | 0.03% | 0.27% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||